Insulet | PODD - Ebitda


Insulet reported $181.7M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Abbott USD 3.27B 178M Dec/2025
Align Technology USD 260.87M 77.03M Dec/2025
AtriCure USD 17.07M 2.79M Mar/2026
Avanos Medical USD 13M 3M Dec/2025
Baxter International USD -447M 873M Dec/2025
Becton, Dickinson and Co. USD 1.71B 433M Dec/2025
Boston Scientific USD 1.16B 213M Dec/2025
Cardinal Health USD 1.09B 109M Mar/2026
Cooper Companies USD 323.4M 13.2M Dec/2025
Dexcom USD 364.5M 57.7M Mar/2026
Edwards Lifesciences USD 70.1M 394.2M Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Globus Medical USD 280.46M 27.86M Dec/2025
ICU Medical USD 98.68M 489K Mar/2026
Insulet USD 181.7M 12.3M Mar/2026
Integra LifeSciences USD 76.18M 28.03M Mar/2026
J&J USD 7.19B 2.32B Dec/2025
Masimo USD 85.5M 6.4M Mar/2026
Medtronic USD 2.81B 119M Mar/2026
Merit Medical Systems USD 97.23M 17.69M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Solventum Corp USD 437M 0 Mar/2026
Stryker USD 1.57B 618M Mar/2026
Tandem Diabetes Care USD 2.73M 30.17M Mar/2026
Teleflex USD 247.07M 575.88M Dec/2025
West Pharmaceutical Services USD 226.2M 7.7M Mar/2026
Zimmer Biomet Holdings USD 759M 120.8M Dec/2025